{
    "clinical_study": {
        "@rank": "52001", 
        "acronym": "apact", 
        "arm_group": [
            {
                "arm_group_label": "nab-Paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2", 
                "arm_group_type": "Experimental", 
                "description": "Treatment Arm A"
            }, 
            {
                "arm_group_label": "Gemcitabine 1000 mg/m2", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment Arm B"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare whether there is a delay or prevention of recurrence\n      or death in subjects with surgically removed pancreatic cancer who then take nab-paclitaxel\n      in combination with gemcitabine compared to those who take gemcitabine alone."
        }, 
        "brief_title": "Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the \"Apact\" Study)", 
        "completion_date": {
            "#text": "October 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreatic Neoplasms", 
            "Digestive System Neoplasms", 
            "Neoplasms by Site", 
            "Neoplasms", 
            "Endocrine Gland Neoplasms", 
            "Pancreatic Diseases", 
            "Digestive System Diseases", 
            "Endocrine System Diseases", 
            "Gemcitabine", 
            "Antimetabolites, Antineoplastic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Neoplasms", 
                "Digestive System Diseases", 
                "Gastrointestinal Diseases", 
                "Digestive System Neoplasms", 
                "Gastrointestinal Neoplasms", 
                "Endocrine System Diseases", 
                "Endocrine Gland Neoplasms", 
                "Neoplasms by Site", 
                "Pancreatic Diseases", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "ABI-007-PANC-003 is a Phase 3, international, multicenter, randomized, open-label,\n      controlled study that will compare the efficacy of nab-paclitaxel in combination with\n      gemcitabine to gemcitabine alone as adjuvant treatment for 6 cycles in patients with\n      surgically resected pancreatic adenocarcinoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Histologically confirmed resected ductal pancreatic adenocarcinoma with\n             macroscopic complete resection (R0 and R1). Subjects with neuroendocrine (and mixed\n             type) tumors are excluded.\n\n             2. Pancreatic cancer surgical staging: T 1-3, N0-1, M0. 3. Subject should be able to\n             start treatment no later than 12 weeks postsurgery.\n\n             4. \u226518 years of age at the time of signing the informed consent form (ICF). 5.\n             Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Acceptable\n             hematology parameters:\n\n               -  Absolute neutrophil count \u22651500 cell/mm3\n\n               -  Platelet count \u2265100,000/mm3\n\n               -  Hemoglobin (Hgb) \u22659 g/dL 7. Acceptable blood chemistry levels:\n\n               -  Aspartate aminotransferase (AST)/ Serum glutamic oxaloacetic transaminase (SGOT)\n                  and Alanine transaminase (ALT)/ Serum glutamic -pyruvic transaminase (SGPT) \u22642.5\n                  \u00d7 upper limit of normal range (ULN)\n\n               -  Total bilirubin \u2264 Upper Limit of Normal (ULN) (subjects with Gilbert's syndrome\n                  can have bilirubin of up to 1.5 x ULN)\n\n               -  Alkaline phosphatase \u2264 2.5 x ULN\n\n               -  Serum creatinine within upper limits of normal or calculated clearance \u226550\n                  mL/min/1.73 m2.  If using creatinine clearance, actual body weight should be\n                  used for calculating creatinine clearance (eg, using the Cockroft-Gault\n                  formula).  For subjects with a Body Mass Index (BMI) >30 kg/m2, lean body weight\n                  should be used instead 8. Cancer antigen (CA)19-9 <100 U/mL assessed within 14\n                  days of randomization 9. Acceptable coagulation studies as demonstrated by\n                  Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) within normal limits\n                  (\u00b115%)\n\n        Exclusion Criteria:\n\n          -  A subject will not be eligible for inclusion in this study if any of the following\n             criteria apply:\n\n               1. Prior neo-adjuvant treatment or radiation therapy for pancreatic adenocarcinoma\n\n               2. Presence of or history of metastatic pancreatic adenocarcinoma\n\n               3. Any other malignancy within 5 years prior to randomization, with the exception\n                  of adequately treated in-situ carcinoma of the cervix, uteri, or nonmelanomatous\n                  skin cancer (all treatment of which should have been completed 6 months prior to\n                  randomization)\n\n               4. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic\n                  therapy, defined as ongoing signs/symptoms related to the infection without\n                  improvement despite appropriate antibiotics, antiviral therapy, and/or other\n                  treatment\n\n               5. Known infection with hepatitis B or C, or history of human immunodeficiency\n                  virus (HIV) infection, or subject receiving immunosuppressive or\n                  myelosuppressive medications that would in the opinion of the investigator,\n                  increase the risk of serious neutropenic complications\n\n               6. History of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any\n                  of their excipients\n\n               7. Serious medical risk factors involving any of the major organ systems, or\n                  serious psychiatric disorders, which could compromise the subject's safety or\n                  the study data integrity. These include, but are not limited to:\n\n                    1. History of connective tissue disorders (eg, lupus, scleroderma, arteritis\n                       nodosa)\n\n                    2. History of interstitial lung disease, slowly progressive dyspnea and\n                       unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis,\n                       pulmonary hypersensitivity pneumonitis or multiple allergies\n\n                    3. History of the following within 6 months prior to Cycle 1 Day 1: a\n                       myocardial infarction, severe/unstable angina pectoris, coronary/peripheral\n                       artery bypass graft, New York Heart Association (NYHA) Class III-IV heart\n                       failure, uncontrolled hypertension, clinically significant cardiac\n                       dysrhythmia or ECG abnormality, cerebrovascular accident, transient\n                       ischemic attack, or seizure disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964430", 
            "org_study_id": "ABI-007-PANC-003", 
            "secondary_id": "2013-003398-91"
        }, 
        "intervention": [
            {
                "arm_group_label": "nab-Paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2", 
                "description": "nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles", 
                "intervention_name": "nab-Paclitaxel 125 mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane"
            }, 
            {
                "arm_group_label": "nab-Paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2", 
                "description": "nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles", 
                "intervention_name": "gemcitabine 1000 mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "Gemcitabine 1000 mg/m2", 
                "description": "Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles", 
                "intervention_name": "gemcitabine 1000 mg/m2", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Resectable pancreatic cancer", 
            "resected", 
            "resectable PDA", 
            "adenocarcinoma", 
            "surgically resected", 
            "adjuvant", 
            "Abraxane", 
            "nab-paclitaxel", 
            "ABI-007", 
            "gemcitabine", 
            "Gemzar", 
            "Phase 3"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "Hellen Diller Family Comprehensive Cancer Center, UCSF"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington Heights", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60005"
                    }, 
                    "name": "Illinois Cancer Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Tennessee Oncology - Chattanooga"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology PLLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Center for Cancer and Blood Disorders"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Ileana Elias, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Ministry of Health", 
                "Australia: Department of Health and Aging Therapeutic Good Administration", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Brazil: Ministry of Health", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Health and Medicines Authority", 
                "Finland: Finnish Medicines Agency", 
                "France: National Agency for the Safety and Medicine and Health Products", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hong Kong: Department of Health", 
                "Hungary: National Institute of Pharmacy", 
                "Italy: Ministry of Health", 
                "Mexico: Ministry of Health", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Singapore: Health Sciences Authority", 
                "Spain: Spanish Agency for Medicines and Health Products", 
                "Sweden: Medical Products Agency", 
                "Taiwan: Taiwan Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time from the date of randomization to the date of disease recurrence or death, whichever is earlier. (Disease recurrence will be determined by independent radiological review of computed tomography (CT) or magnetic resonance imaging (MRI) scans.)", 
            "measure": "Disease Free Survival (DFS)", 
            "safety_issue": "No", 
            "time_frame": "up to approximately 9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from the date of randomization to the date of death", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 18 months"
            }, 
            {
                "description": "Assessment based on AEs, SAEs, laboratory abnormalities.", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to approximately 18 months"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}